Stock Alert: BioAtla (BCAB) Trades 3.77% Lower May 13

Equities Staff  |

Today, BioAtla Inc (NASDAQ:BCAB) lost $0.09 to end the day Friday at $2.30.

The company began the day at $2.42 and shares fluctuated between $2.47 and $2.29 with 550,078 shares trading hands.

BioAtla is averaging 736,460 shares traded over the last 30 days. They have shed 87.82% YTD.

BioAtla is set to release earnings on 2022-08-09.

For technical charts, analysis, and more on BioAtla visit the company profile.

About BioAtla Inc

BioAtla® is a San Diego biotech company that develops novel monoclonal antibody and cell based therapeutics using our proprietary Conditionally Active Biologics™ (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!™) platforms. These and other proprietary technologies (protected by more than 150 issued patents and patent applications) allow it to develop novel biologics (CABs) that are better drugs in multiple ways including more selective targeting of cancer tissue and improved manufacturability. Improved selectivity for the tumor microenvironment (TME), even when the target is also found in normal tissue, not only improves safety and thus therapeutic index but also expands the universe of potential drug targets, enabling the treatment of previously untreatable cancers.

To get more information on BioAtla Inc and to follow the company's latest updates, you can visit the company's profile page here: BioAtla Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:

Trending Articles

Big Lots Down 18% in Premarket Trading Friday on Surprise Missed Earnings
Modine Posts Strong Rebound in Fiscal Q4, Raises 2023 Guidance
Dollar Tree Posts Record First Quarter, Leads Nasdaq Gainers
Kohl's Still in Play To Be Acquired
Chinook Therapeutics Raises $105 Million for Kidney Disease Therapies
Market Conditions Driving Higher Base Level for VIX Volatility Index
Will New AT&T, Dish Co-opetition Deal Work: Jeff Kagan
Cisco Down 12% in Premarket Trading Thursday After Top Line Miss and Lower Forecast

Market Movers

Sponsored Financial Content